Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.37 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | RXRB | P28702 | 1/20 | 0.35 |
| ▸ | RXRG | P48443 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.31 |
| ▸ | ATR | Q13535 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15265623 | 0.85 | ATR (0.38) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL18260924 | 0.85 | CYP4F2 (0.35) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL767589 | 0.84 | NPC1 (0.37) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL20163367 | 0.83 | CYP4F2 (0.34) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL15278368 | 0.83 | RET (0.35) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL19493353 | 0.83 | CYP4F2 (0.34) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL18290023 | 0.83 | CYP4F2 (0.34) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL767386 | 0.83 | CYP4F2 (0.34) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL18260694 | 0.82 | CYP4F2 (0.34) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL18260817 | 0.82 | RORC (0.34) | CYP4F2CYP4A11RXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3544967-B1 | SALTS OF INDAZOLE DERIVATIVE AND CRYSTALS THEREOF | EISAI R&D MAN CO LTD (JP) | 2023-06-28 | — | — | EP | disclosed |
| US-20230055961-A1 | PENTAFLUOROBENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | DUNAD THERAPEUTICS LTD. (GB) | 2023-02-23 | — | — | US | disclosed |
| EP-3981766-A1 | INDAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Eisai R&D Management Co., Ltd. (JP) | 2022-04-13 | — | — | EP | disclosed |
| EP-3981766-A1 | INDAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Eisai R&D Management Co., Ltd. (JP) | 2022-04-13 | — | — | EP | disclosed |
| CN-113024466-A | Tetra-substituted olefin compound and use thereof | 卫材 R&D 管理有限公司 | 2021-06-25 | — | — | CN | disclosed |
| CN-109790141-B | Salts of indazole derivatives and crystals thereof | 卫材 R&D 管理有限公司 | 2021-06-11 | — | — | CN | disclosed |
| WO-2021099842-A1 | PENTAFLUOROBENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | 2692372 ONTARIO INC. (CA) | 2021-05-27 | — | — | WO | disclosed |
| CN-107847498-B | Tetra-substituted olefin compound and use thereof | 卫材R&D管理有限公司 | 2021-04-13 | — | — | CN | disclosed |
| US-10851065-B2 | Tetrasubstituted alkene compounds and their use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-12-01 | — | — | US | disclosed |
| US-10851065-B2 | Tetrasubstituted alkene compounds and their use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-12-01 | — | — | US | disclosed |
| US-20180127378-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-05-10 | — | — | US | disclosed |
| EP-3302471-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE | Eisai R&D Management Co., Ltd. (JP) | 2018-04-11 | — | — | EP | disclosed |
| US-9796683-B2 | Tetrasubstituted alkene compounds and their use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-10-24 | — | — | US | disclosed |
| US-9796683-B2 | Tetrasubstituted alkene compounds and their use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-10-24 | — | — | US | disclosed |
| US-9796683-B2 | Tetrasubstituted alkene compounds and their use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-10-24 | — | — | US | disclosed |
| WO-2016196346-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-12-08 | — | — | WO | disclosed |
| WO-2016196337-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2016-12-08 | — | — | WO | disclosed |
| WO-2016196337-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2016-12-08 | — | — | WO | disclosed |
| WO-2016196346-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-12-08 | — | — | WO | disclosed |
| US-20160347717-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10851065-B2 | Tetrasubstituted alkene compounds and their use | BRCA1, ESR2, ESR1 | CYP4F2 3533/4885CYP4A11 2858/4885RXRA 544/4885 |
| US-20160347717-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE | BRCA1, ESR2, ESR1 | CYP4F2 3533/4885CYP4A11 2858/4885RXRA 544/4885 |
| US-20230055961-A1 | PENTAFLUOROBENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | FURIN, PFAS, CFTR | CYP4F2 26/4885CYP4A11 332/4885RXRA 1474/4885 |
| US-20180127378-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE | BRCA1, ESR2, ESR1 | CYP4F2 3533/4885CYP4A11 2858/4885RXRA 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.